Hjem › Steatotisk leversykdom › Indiana
Kliniske studier for Steatotisk leversykdom i Indiana
9 studier for Steatotisk leversykdom søker deltakere på steder i Indiana.
Byer i Indiana
Offisiell studietekst (engelsk)
A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH
- 89bio Clinical Study Site, Hammond
- 89bio Clinical Study Site, New Albany
- 89bio Clinical Study Site, South Bend
RekruttererFase 3
Alder 18 til 75 · Alle kjønn · Oppdatert 5. okt. 2026 · NCT06419374A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)
- 89bio Clinical Study Site, Hammond
- 89bio Clinical Study Site, New Albany
- 89bio Clinical Study Site, South Bend
RekruttererFase 3
Alder 18 til 80 · Alle kjønn · Oppdatert 5. okt. 2026 · NCT06318169A Precision Medicine Approach Using Gene Silencing to Treat a Chronic Liver Disease Called Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Adult Participants at Increased Genetic Risk for This Condition
- Indiana University School of Medicine, Indianapolis
RekruttererFase 2
Alder 18 til 75 · Alle kjønn · Oppdatert 25. sep. 2026 · NCT05519475A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
- Indiana University Health University Hospital, Indianapolis
- Gastroenterology Health Partners, New Albany
- Deaconess Clinic- Gateway, Newburgh
- og 1 flere
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 22. sep. 2026 · NCT07165028A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH
- Akero Clinical Study Site, Hammond
- Akero Clinical Study Site, Indianapolis
- Akero Clinical Study Site, South Bend
RekruttererFase 3
Alder 18 til 80 · Alle kjønn · Oppdatert 21. sep. 2026 · NCT06528314A Study of a Thyroid Hormone Receptor Beta Isoform (THRβ) Agonist and an Semicarbazide Sensitive Amine Oxidase (SSAO) Inhibitor, Alone and in Combination, in Adults With Presumed Metabolic Dysfunction-associated Steatohepatitis (MASH)
- Digestive Research Alliance of Michiana, South Bend
RekruttererFase 2
Alder 18 til 75 · Alle kjønn · Oppdatert 9. sep. 2026 · NCT07288138A Study to Investigate the Safety and Efficacy of GSK4532990 Compared With Placebo in Adult Participants Aged 18 to 70 Years With Alcohol-related Liver Disease
- GSK Investigational Site, Indianapolis
RekruttererFase 2
Alder 18 til 70 · Alle kjønn · Oppdatert 3. aug. 2026 · NCT06613698Fibrosis Lessens After Metabolic Surgery
- Indiana University, Indianapolis
RekruttererFase 4Frivillige helsepersonell ønskes velkommen
Alder 18 til 75 · Alle kjønn · Oppdatert 31. jul. 2026 · NCT06374875Non-Invasive Quantification of Liver Health in NASH (N-QUAN)
- Indiana University Health, Indianapolis
Rekrutterer
Alder 18 til 75 · Alle kjønn · Oppdatert 19. mai 2026 · NCT04054310Fra ClinicalTrials.gov, data hentet 6. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.